BLU 554

Drug Profile

BLU 554

Alternative Names: BLU-554

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blueprint Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cholangiocarcinoma; Hepatocellular carcinoma

Most Recent Events

  • 01 Aug 2018 Blueprint Medicines plans to file an IND application with the CFDA in China for Hepatocellular carcinoma (Combination therapy) by the end of 2018
  • 04 Jun 2018 BLU 554 licensed to CStone Pharmaceuticals in China, Macau, Taiwan and Hong Kong
  • 04 Jun 2018 CStone Pharmaceuticals plans a proof-of-concept trial of BLU 554 in combination with CS 1001 for hepatocellular carcinoma in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top